These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. Wilson WH; Bates SE; Fojo A; Chabner BA J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R25-9. PubMed ID: 8698739 [TBL] [Abstract][Full Text] [Related]
5. Dexverapamil as resistance modifier in acute myeloid leukaemia. Pirker R; Zöchbauer S; Kupper H; Lassmann A; Gsur A; Frass M; Krajnik G; Knöbl P; Lechner K J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R21-4. PubMed ID: 8698738 [TBL] [Abstract][Full Text] [Related]
6. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Thürlimann B; Kröger N; Greiner J; Mross K; Schüller J; Schernhammer E; Schumacher K; Gastl G; Hartlapp J; Kupper H J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R3-6. PubMed ID: 8698740 [TBL] [Abstract][Full Text] [Related]
7. Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results. Gatzemeier U; Schneider A; von Pawel J J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R17-20. PubMed ID: 8698737 [TBL] [Abstract][Full Text] [Related]
8. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574 [TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539 [TBL] [Abstract][Full Text] [Related]
11. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540 [TBL] [Abstract][Full Text] [Related]
12. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587 [TBL] [Abstract][Full Text] [Related]
13. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W; Kornek G; Raderer M; Koperna-Mach K; Müller C; Karner J; Kastner J; Tetzner C J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R7-10. PubMed ID: 8698741 [TBL] [Abstract][Full Text] [Related]
16. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064 [TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Liu JH; Yang MH; Fan FS; Yen CC; Wang WS; Chang YH; Chen KK; Chen PM Urology; 2001 Apr; 57(4):650-4. PubMed ID: 11306370 [TBL] [Abstract][Full Text] [Related]
18. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Lehnert M; Mross K; Schueller J; Thuerlimann B; Kroeger N; Kupper H Br J Cancer; 1998 Apr; 77(7):1155-63. PubMed ID: 9569055 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]